Abstract
The objective of this exploratory modelling study was to estimate the effects of second-trimester, ultrasound-based antenatal detection strategies for vasa praevia (VP) in a hypothetical cohort of pregnant women. For this, a decision-analytic tree model was developed covering four discrete detection pathways/strategies: no screening; screening targeted at women undergoing in-vitro fertilisation (IVF); screening targeted at women with low-lying placentas (LLP); screening targeted at women with velamentous cord insertion (VCI) or a bilobed or succenturiate (BL/S) placenta. Main outcome measures were the number of referrals to transvaginal sonography (TVS), diagnosed and undiagnosed cases of VP, overdetected cases of VCI, and VP-associated perinatal mortality. The greatest number of referrals to TVS occurred in the LLP-based (2,083) and VCI-based screening (1,319) pathways. These two pathways also led to the highest proportions of pregnancies diagnosed with VP (VCI-based screening: 552 [78.9% of all pregnancies]; LLP-based: 371 [53.5%]) and the lowest proportions of VP leading to perinatal death (VCI-based screening: 100 [14.2%]; LLP-based: 196 [28.0%]). In contrast, the IVF-based pathway resulted in 66 TVS referrals, 50 VP diagnoses (7.1% of all VP pregnancies), and 368 (52.6%) VP-associated perinatal deaths which was comparable to the no screening pathway (380 [54.3%]). The VCI-based pathway resulted in the greatest detection of VCI (14,238 [99.1%]), followed by the IVF-based pathway (443 [3.1%]); no VCI detection occurred in the LLP-based or no screening pathways. In conclusion, the model results suggest that a targeted LLP-based approach could detect a substantial proportion of VP cases, while avoiding VCI overdetection and requiring minimal changes to current clinical practice. High-quality data is required to explore the clinical and cost-effectiveness of this and other detection strategies further. This is necessary to provide a robust basis for future discussion about routine screening for VP.
Funder
UK National Screening Committee
Publisher
Public Library of Science (PLoS)
Reference47 articles.
1. Screening for vasa praevia in the second trimester of pregnacy—External review against programme appraisal criteria for the UK National Screening Committee (UK NSC).;UK National Screening Committee,2017
2. Vasa previa: the impact of prenatal diagnosis on outcomes.;Y Oyelese;Obstetrics and gynecology,2004
3. Prenatal sonographic diagnosis of vasa previa: ultrasound findings and obstetric outcome in ten cases.;V Catanzarite;Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.,2001
4. Incidence of and risk indicators for vasa praevia: a systematic review.;L Ruiter;BJOG: an international journal of obstetrics and gynaecology,2016
5. Vasa Praevia: Diagnosis and Management (RCOG Green‐top Guideline No. 27b). Available from: https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/vasa-praevia-diagnosis-and-management-green-top-guideline-27b/ 2018.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献